Details of the Drug

General Information of Drug (ID: DM20LIM)

• Drug Name: Bremelanotide
• Synonyms: Bremelanotide (USAN/INN); PT-141; Rekynda

Indication

Disease Entry	ICD 11	Status	REF
Hypoactive sexual desire dysfunction	HA00	Approved	[1]
Erectile dysfunction	HA01.1	Phase 3	[2]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 4:
  Molecular Weight (mw); 1025.2
  Logarithm of the Partition Coefficient (xlogp); 0.7
  Rotatable Bond Count (rotbonds); 17
  Hydrogen Bond Donor Count (hbonddonor); 13
  Hydrogen Bond Acceptor Count (hbondacc); 12
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 276 mcgh/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 72.8 mcg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.0 h [3]
  Clearance: The clearance of drug is 6.5 +/- 1.0 L/h [3]
  Elimination: 64.8% of a radiolabelled dose is excreted in the urine and 22.8% of the dose is recovered in the feces [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2.7 hours [3]
  Metabolism: The drug is metabolized via the multiple hydrolysis reactions [3]
  Vd: The volume of distribution (Vd) of drug is 25.0 +/- 5.8 L [3]
• Chemical Identifiers:
  Formula: C50H68N14O10
  IUPAC Name: (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
  Canonical SMILES: CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C
  InChI: InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1
  InChIKey: FFHBJDQSGDNCIV-MFVUMRCOSA-N
• Cross-matching ID:
  PubChem CID: 9941379
  CAS Number: 189691-06-3
  DrugBank ID: DB11653
  TTD ID: D0X9PF
  ACDINA ID: D00888
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanocortin receptor 1 (MC1R)	TT0MV2T	MSHR_HUMAN	Agonist	[1]
Melanocortin receptor 4 (MC4R)	TTD0CIQ	MC4R_HUMAN	Agonist	[1]

Molecular Expression Atlas of This Drug

• The Studied Disease: Hypoactive sexual desire dysfunction
• ICD Disease Classification: HA00

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Melanocortin receptor 4 (MC4R)	DTT	MC4R	5.64E-01	-0.04	-0.18

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydrochloric acid	E00015	313	Acidulant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Bremelanotide 1.75 mg/0.3 ml Injection	1.75 mg/0.3 ml	Injection	Subcutaneous

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
• [3] FDA Approved Drug Products: Bremelanotide Injection